Press Releases + News Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryJun 24, 2009 PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS NMR Studies Further Define DAVANAT®'s Mechanism of Action with Galectin Receptors Found on Solid Tumors View HTML PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS 17.2 KB Toggle SummaryMay 30, 2009 PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS 18.4 KB Toggle SummaryMay 15, 2009 Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results View HTML Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results 19.6 KB Toggle SummaryApr 29, 2009 PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA View HTML PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA 17.1 KB Toggle SummaryApr 15, 2009 Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated View HTML Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated 17.7 KB Toggle SummaryMar 29, 2009 PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA View HTML PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA 20.7 KB Toggle SummaryFeb 17, 2009 PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT View HTML PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT 13.3 KB Toggle SummaryFeb 17, 2009 PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING View HTML PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING 13.3 KB Toggle SummaryFeb 17, 2009 PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER Gil Amelio, Ph.D., Jim Czirr, Rod Martin, J.D., Peter Traber, M.D., Named to the Company's Board of Directors View HTML PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER 13.3 KB Toggle SummaryFeb 03, 2009 PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT View HTML PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT 16.6 KB Pagination First page First Previous page Previous … Page 36 Page 37 Page 38 Current page 39
PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS 17.2 KB
PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA 17.1 KB
Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated 17.7 KB
PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA 20.7 KB
PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT 13.3 KB
